Efficacy and Safety of Idelalisib and Rituximab for Previously Treated CLL
Richard R. Furman, MD, Richard A. Stratton Assistant Professor in Hematology and Oncology, Weill Cornell Medical College, gives an overview of the efficacy and safety of idelalisib and rituximab for previously treated CLL.
Clinical Pearls: Results
Richard R. Furman, MD, Richard A. Stratton Assistant Professor in Hematology and Oncology, Weill Cornell Medical College, gives an overview of the efficacy and safety of idelalisib and rituximab for previously treated chronic lymphocytic leukemia (CLL).
- Idelalisib + rituximab demonstrated an improvement in progression-free survival (PFS) compared with placebo + rituximab [HR = 0.15]
- Median PFS was not reached in idelalisib arm and was 5.5 months in placebo arm
- Overall survival benefit was also identified in idelalisib arm
Clinical Pearls: Adverse Events
- There was a decrease in the risk of infusion reaction in the idelalisib arm
- 6 patients in the idelalisib arm experienced transaminitis
- In this analysis, patients treated with idelalisib did not see an increased risk of diarrhea
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
